Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib

Publisher： John Wiley & Sons Inc

E-ISSN： 1545-5017|65|3|pbc.26893-pbc.26893

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.65, Iss.3, 2018-03, pp. : n/a-n/a

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Extended Antitumor Responseof a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-05 ,pp. : 343-348

Karger

Access to resources Recommend Favorite

Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation‐positive metastatic melanoma, including recognition and management of rare presentations

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 4, 2015-10 ,pp. : 1024-1031

John Wiley & Sons Inc

Access to resources Recommend Favorite

Distinctive clinical and dermoscopic features of BRAF V600K mutated melanomas

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 172, Iss. 5, 2015-05 ,pp. : 1438-1440

John Wiley & Sons Inc

Access to resources Recommend Favorite

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma

By  

Case Reports in Oncology, Vol. 9, Iss. 1, 2016-04 ,pp. : 241-245

Karger

Access to resources Recommend Favorite

BRAF V600E mutational status in bile duct adenomas and hamartomas

By  

HISTOPATHOLOGY, Vol. 67, Iss. 4, 2015-10 ,pp. : 562-567

John Wiley & Sons Inc

Access to resources Recommend Favorite